Quick Answer
Relay Therapeutics, Inc. reported Total Revenue of $15.36 million for fiscal year 2025.
Relay Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $15.36M | +53.4% |
| 2024 | $10.01M | -60.8% |
| 2023 | $25.55M | +1749.8% |
| 2022 | $1.38M | -54.4% |
| 2021 | $3.03M | -96.3% |
| 2020 | $82.65M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | — | -100.0% |
| June 30, 2025 | $677.0K | — | -91.2% |
| March 31, 2025 | $7.68M | -23.3% | — |
| September 30, 2024 | $0.00 | -100.0% | — |
| June 30, 2024 | $0.00 | -100.0% | -100.0% |
| March 31, 2024 | $10.01M | +4327.9% | -60.3% |
| September 30, 2023 | $25.20M | +7226.2% | +21078.2% |
| June 30, 2023 | $119.0K | -67.4% | -47.3% |
- Relay Therapeutics, Inc. showed an increase of +53.4% in Total Revenue compared to the prior fiscal year.
- Over the 2020–2025 period, Relay Therapeutics, Inc.’s total revenue has declined by 81.4% (from $82.65 million to $15.36 million).
- The most recent figure is from Relay Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: